Obecabatagene Autoleucel

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.

CHICAGO — Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel, interim results of the pivotal phase 2 FELIX trial showed.

The FDA granted regenerative medicine advanced therapy designation to obecabatagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia.